This invention was made at least in part with funds provided under grants from the United States Government (National Institutes of Health Grants AI23360-08, AI12069, CA55601 and CA34183). Therefore, the U.S. Government has certain rights in this invention.
Entry |
---|
Fahey et al., Clin. & Exp. Immunol., vol. 88: 1-5, Jan. 1992.* |
Hirsch et al., New England Journal of Medicine, vol. 328: 1686-1695, Jun. 1993.* |
Callebaut et al., Science, vol. 262: 2045-2050, Dec. 1993.* |
Scott et al., Leukemia Research, vol. 12: 129-134, Feb. 1988.* |
Duke-Cohan et al., J. of Immunology, vol. 156: 1714-1721, Aug. 1996.* |
Lerner, Nature, vol. 299: 592-596, Oct. 1982.* |
Fox et al., “Ta1, A Novel 105 KD Human T Cell Activation Antigen Defined By A Monoclonal Antibody,” J. Immunol. 133:1250-1256 (1984). |
Morimoto et al., 1F7, A Novel Cell Surface Molecule, Involved In Helper Function Of CD4 Cells, J. Immunol. 143:3430-3439 (1989). |
Hafler et al., “Antigen Reactive Memory T Cells Are Defined By Ta11 ,” J. Immunol. 137:414-418 (1986). |
Stein et al., “Leukocyte Typing IV” (Knapp, W., Oxford University Press, Oxford, Great Britian pp. 412-415 (1989). |
Hegen et al., “The T Cell Triggering Molecule Tp103 Is Associated With Dipeptidyl Aminopeptidase IV Activity1,” J. Immunol. 144:2908-2914 (1990). |
Ulmer et al., “CD26 Antigen is a Surface Dipeptidyl Peptidase IV (DPPIV) as Characterized by Monoclonal Antibodies Clone TII-19-4-7 and 4EL1C7,” Scand. J. Immunol. 31:429-435 (1990). |
Tanaka et al., “The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity,” Proc. Natl. Acad. Sci. USA 90:4586-4590 (1993). |
Yaron et al., “Proline-Dependent Structural and Biological Properties of Peptides and Proteins,” Crit. Rev. Biochem. Mol. Biol. 28:31-81 (1993). |
Heymann et al., “Liver Dipeptidyl Aminopeptidase IV Hydrolyzes Substance P,” FEBS Lett. 91:360-364 (1978). |
Dang et al., “Comitogenic Effect of Solid-Phase Immobilized Anti-1F7 On Human CD4 T Cell Activation Via CD3 And CD2 Pathways1 ,” J. Immunol. 144:4092-4100 (1990). |
Tanaka et al., “Cloning and Functional Expression of the T Cell Activation Antigen CD261,” J. Immunol. 149:481-486 (1992). |
Torimoto e tal., Coassociation of CD26 (Dipeptidyl Peptidase IV) With CD45 On The Surface Of Human T Lymphocytes1, J. Immunol. 147:2514-2517 (1991). |
Kameoka et al., “Direct Association of Adenosine Deaminase with a T Cell Activation Antigen, CD26,” Science 261:466-469 (1993). |
Buc et al., “Influence of adenosine deaminase inhibition on the phosphoinositide turnover in the initial stages of human T cell activation*,” Eur. J. Immunol. 20:611-615 (1990). |
Tanaka et al., “Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV,” Proc. Natl. Acad. Sci. (USA) 91:3082-3086 (1994). |
Torimoto et al., “Biochemical Characterization Of CD26 (Dipeptidyl Peptidase IV): Functional Comparison Of Distinct Epitopes Recognized By Various Anti-CD26 Monoclonal Antibodies,” Mol. Immunol. 29:183-192 (1992). |
Morrison et al., “A Marker for Neoplastic Progression of Human Melanocytes Is a Cell Surface Ectopeptidase,” J. Exp. Med. 177:1135-1143 (1993). |
Kyouden et al., “Purification and Characterization of Dipeptidyl Peptidase IV in Rat Liver Lysosomal Membranes1,” J. Biochem. 111:770-777 (1992). |
Hino et al., “X-Prolyl Dipeptidyl-Aminopeptidase Activity, with X-Proline p-Nitroanilides as Substrates, in Normal and Pathological Human Sera,” Clin. Chem. 22:1256-1261 (1976). |
Vanhoof et al., “Distribution of Proline-Specific Aminopeptidases in Human Tissues and Body Fluids,” Eur. J. Clin. Biochem. 30:333-338 (1992). |
Stancikova et al., “Dipeptidyl peptidase IV in patients with systemic lupus erythematosus,” Clin. Exp. Rheumatol. : 10:381-385 (1992). |
Hama et al., “Changes in form of dipeptidyl-aminopeptidase IV in urine from patients with renal disease,” Clin. Chim. Acta. 113:217-221 (1981). |
Chikuma et al., “Purification and Properties of Dipeptidyl Peptidase IV from Human Urine,” Biol. Chem. Hoppe-Seyler 371:325-330 (1990). |
Fleischer et al., “CD26: a surface protease involved in T-cell activation,” Immunology Today 15:180-184 (1994). |
Schrader et al., “Purification of an Adenosine Deaminase Complexing Protein from Human Plasma,” J. Biol. Chem.254:11964-11968 (1979). |
Darmoul et al., “Isolation of a cDNA probe for the human intestinal depeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2,” Ann. Hum. Genet. 54:191-197 (1990). |
Chobert et al., “Tissue-specific Expression of Two γ-Glutamyl Transpeptidase mRNAs with Alternative 5' Ends Encoded by a Single Copy Gene in the Rat*,” J. Biol. Chem. 265:2352-2357 (1990). |
Wada et al., Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family, Proc. Natl. Acad. Sci. (USA) 89:197-201 (1992). |
Scanlan et al., “Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers,” Proc. Natl. Acad. Sci. (USA) 91:5657-5661 (1994). |
Bernard et al., “Structure of the Mouse Dipeptidyl Peptidase IV (CD26) Gene,” Biochemistry 33:15204-15214 (1994). |
Ollis et al., “The α/β hydrolase fold,” Protein Engineering 5:197-211 (1992). |
Hirschhorn et al., “Isozymes: Current Topics in Biological and Medical Research,” 4:131-157 (1980). |
Niedzwicki et al., “Plasma Adenosine Deaminase,2 Is a Marker for Human Immunodeficiency Virus-1 Seroconversion,” Am. J. Hematol. 37:152-155 (1991). |
Ungerer et al., “Serum Adenosine Deaminase: Isoenzymes and Diagnostic Application,” Clin. Chem. 38:1322-1326 (1992). |
Matsuda et al., “Serum Adenosine Deaminase 2 and Neopterin Levels Are Increased in a Majority of Hemophiliacs of Infection with Human Immunodeficiency Virus Type I,” Clin. Infec. Dis. 16:260-264 (1993). |